Drug intelligence / Profile preview

PYC35

Development stage: Unknown
Lead developer: Phylogica
Modality: Peptides

Overview

**PYC35** is a lead candidate from a family of anti-inflammatory **Phylomer peptides** developed by **Phylogica Ltd**. These proprietary cyclic peptides target the **AP-1 pathway**, a key transcription factor complex mediating inflammatory responses, including in wound healing and skin repair. Phylogica has demonstrated **PYC35**'s efficacy in reducing AP-1 signaling to promote wound repair in validated animal models, such as severe skin burns, positioning it as a potential therapeutic for inflammatory conditions and tissue regeneration.[1][5][9]

Targets

FOS (Activator Protein 1)

Beyond the preview

Go deeper on PYC35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYC35.

Explore the full profile